ArticlePloS one2010
The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Molecular profiling of high-level athlete skeletal muscle after acute endurance or resistance exercise - A systems biology approach.Molecular metabolism · 2024Article
- RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome.Human genomics · 2023Review
- Proteomic characterization of primary cultured myocytes in a fish model at different myogenesis stages.Scientific reports · 2019Article
- Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data.Molecular cell · 2018Article
- Identification of MyoD Interactome Using Tandem Affinity Purification Coupled to Mass Spectrometry.Journal of visualized experiments : JoVE · 2016Article
- Runx1 Transcription Factor Is Required for Myoblasts Proliferation during Muscle Regeneration.PLoS genetics · 2015Article
- miR-30 family microRNAs regulate myogenic differentiation and provide negative feedback on the microRNA pathway.PloS one · 2015Article
- Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.Blood · 2014Article
- The SWI/SNF subunit/tumor suppressor BAF47/INI1 is essential in cell cycle arrest upon skeletal muscle terminal differentiation.PloS one · 2014Article
- Identification of cis-regulatory modules in promoters of human genes exploiting mutual positioning of transcription factors.Nucleic acids research · 2013Article
- Review
- Proteomic and functional analyses reveal the role of chromatin reader SFMBT1 in regulating epigenetic silencing and the myogenic gene program.The Journal of biological chemistry · 2013Article
- The histone- and PRMT5-associated protein COPR5 is required for myogenic differentiation.Cell death and differentiation · 2012Article
- Genome-wide mapping of Sox6 binding sites in skeletal muscle reveals both direct and indirect regulation of muscle terminal differentiation by Sox6.BMC developmental biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCore Binding Factor or CBF is a transcription factor composed of two subunits, Runx1/AML-1 and CBF beta or CBFbeta. CBF was originally described as a regulator of hematopoiesis. METHODOLOGY/PRINCIPAL
findingsHere we show that CBF is involved in the control of skeletal muscle terminal differentiation. Indeed, downregulation of either Runx1 or CBFbeta protein level accelerates cell cycle exit and muscle terminal differentiation. Conversely, overexpression of CBFbeta in myoblasts slows terminal differentiation. CBF interacts directly with the master myogenic transcription factor MyoD, preferentially in proliferating myoblasts, via Runx1 subunit. In addition, we show a preferential recruitment of Runx1 protein to MyoD target genes in proliferating myoblasts. The MyoD/CBF complex contains several chromatin modifying enzymes that inhibits MyoD activity, such as HDACs, Suv39h1 and HP1beta. When overexpressed, CBFbeta induced an inhibition of activating histone modification marks concomitant with an increase in repressive modifications at MyoD target promoters. CONCLUSIONS/SIGNIFICANCE: Taken together, our data show a new role for Runx1/CBFbeta in the control of the proliferation/differentiation in skeletal myoblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.